Top

Published in:

01-04-2009 | Original Article

Gene expression in blood of subjects with Duchenne muscular dystrophy

Authors: Brenda Wong, Donald L. Gilbert, Wynn L. Walker, Isaac H. Liao, Lisa Lit, Boryana Stamova, Glen Jickling, Michelle Apperson, Frank R. Sharp

Published in: Neurogenetics | Issue 2/2009

Abstract

The objective of this study was to examine RNA expression in blood of subjects with Duchenne muscular dystrophy (DMD). Whole blood was collected into PAX gene tubes and RNA was isolated for 3- to 20-year-old males with DMD (n = 34) and for age- and gender-matched normal healthy controls (n = 21). DMD was confirmed by genetic testing in all subjects. RNA expression was measured on Affymetrix whole-genome human U133 Plus 2.0 GeneChips. Using a Benjamini–Hochberg false discovery rate of 0.05 to correct for multiple comparisons, an unpaired t test for DMD versus controls yielded 10,763 regulated probes with no fold change cutoff, 1,467 probes with >|1.5|-fold change, 191 probes with >|2.0|-fold change, and 59 probes with a >|2.5|-fold change. These genes (probes) separated DMD from controls using cluster analyses. Almost all of the genes regulated in peripheral blood were different from the genes reported to be regulated in diseased muscle of subjects with DMD. It is proposed that the genes regulated in blood of subjects with Duchenne muscular dystrophy are indicative, at least in part, of the immune response to the diseased DMD muscle. The regulated genes might be used to monitor therapy or provide novel targets for immune-directed therapy for DMD.

Available only for authorised users

Tidball JG, Wehling-Henricks M (2005) Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. Curr Opin Rheumatol 17:707–713 doi:10.1097/01.bor.0000179948.65895.1a CrossRefPubMed

Spencer MJ, Tidball JG (2001) Do immune cells promote the pathology of dystrophin-deficient myopathies? Neuromuscul Disord 11:556–564 doi:10.1016/S0960-8966(01)00198-5 CrossRefPubMed

Moxley RT 3rd, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, Baumbach L, McDonald C, Sussman M, Wade C (2005) Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 64:13–20PubMed

Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP, Cwik VA, Pandya S, Robison J et al (1993) Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 43:520–527PubMed

Bromberg MB, Wald JJ, Forshew DA, Feldman EL, Albers JW (1997) Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci 150:59–62 doi:10.1016/S0022-510X(97)05370-7 CrossRefPubMed

Chen YW, Zhao P, Borup R, Hoffman EP (2000) Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol 151:1321–1336 doi:10.1083/jcb.151.6.1321 CrossRefPubMed

Haslett JN, Sanoudou D, Kho AT, Han M, Bennett RR, Kohane IS, Beggs AH, Kunkel LM (2003) Gene expression profiling of Duchenne muscular dystrophy skeletal muscle. Neurogenetics 4:163–171 doi:10.1007/s10048-003-0148-x CrossRefPubMed

Raju R, Dalakas MC (2005) Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128:1887–1896 doi:10.1093/brain/awh518 CrossRefPubMed

Tang Y, Schapiro MB, Franz DN, Patterson BJ, Hickey FJ, Schorry EK, Hopkin RJ, Wylie M, Narayan T, Glauser TA, Gilbert DL, Hershey AD, Sharp FR (2004) Blood expression profiles for tuberous sclerosis complex 2, neurofibromatosis type 1, and Down’s syndrome. Ann Neurol 56:808–814 doi:10.1002/ana.20291 CrossRefPubMed

10.

Tang Y, Xu H, Du X, Lit L, Walker W, Lu A, Ran R, Gregg JP, Reilly M, Pancioli A, Khoury JC, Sauerbeck LR, Carrozzella JA, Spilker J, Clark J, Wagner KR, Jauch EC, Chang DJ, Verro P, Broderick JP, Sharp FR (2006) Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J Cereb Blood Flow Metab 26:1089–1102 doi:10.1038/sj.jcbfm.9600264 CrossRefPubMed

11.

Walker WL, Liao IH, Gilbert DL, Wong B, Pollard KS, McCulloch CE, Lit L, Sharp FR (2008) Empirical Bayes accommodation of batch-effects in microarray data using identical replicate reference samples: application to RNA expression profiling of blood from Duchenne muscular dystrophy patients. BMC Genomics 20:494–501 doi:10.1186/1471-2164-9-494 CrossRef

12.

Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98:5116–5121 doi:10.1073/pnas.091062498 CrossRefPubMed

13.

Tibshirani R, Hastie T, Narasimhan B, Chu G (2002) Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99:6567–6572 doi:10.1073/pnas.082099299 CrossRefPubMed

14.

Ransohoff DE (2004) Rules of evidence for cancer molecular marker discovery and validation. Nat Rev Cancer 4:309–314 doi:10.1038/nrc1322 CrossRefPubMed

15.

Shanmuga Sundaram J, Mohana Rao V, Meena AK, Anandaraj MP (2006) Altered expression, intracellular distribution and activity of lymphocyte calpain II in Duchenne muscular dystrophy. Clin Chim Acta 373:82–87 doi:10.1016/j.cca.2006.05.004 CrossRefPubMed

16.

McDouall RM, Dunn MJ, Dubowitz V (1990) Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J Neurol Sci 99:199–217 doi:10.1016/0022-510X(90)90156-H CrossRefPubMed

17.

Gussoni E, Pavlath GK, Miller RG, Panzara MA, Powell M, Blau HM, Steinman L (1994) Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy. J Immunol 153:4798–4805PubMed

18.

Du X, Tang Y, Xu H, Lit L, Walker W, Ashwood P, Gregg JP, Sharp FR (2006) Genomic profiles for human peripheral blood T cells, B cells, natural killer cells, monocytes, and polymorphonuclear cells: comparisons to ischemic stroke, migraine, and Tourette syndrome. Genomics 87:693–703 doi:10.1016/j.ygeno.2006.02.003 CrossRefPubMed

19.

Golumbek PT, Keeling RM, Connolly AM (2007) Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout. Neuromuscul Disord 17:376–384 doi:10.1016/j.nmd.2007.02.005 CrossRefPubMed

20.

Gaud A, Simon JM, Witzel T, Carre-Pierrat M, Wermuth CG, Segalat L (2004) Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans. Neuromuscul Disord 14:365–370 doi:10.1016/j.nmd.2004.02.011 CrossRefPubMed

21.

Collins J, Wong B, McCullough A, Quinlan J (2006) The effects of prednisone on exercise-induced muscle damage in mdx mice. Neuromuscul Disord 16:706 doi:10.1016/j.nmd.2006.05.202 CrossRef

22.

Rando TA (2001) The dystrophin-glycoprotein complex, cellular signaling, and the regulation of cell survival in the muscular dystrophies. Muscle Nerve 24:1575–1594 doi:10.1002/mus.1192 CrossRefPubMed

23.

Langenbach KJ, Rando TA (2002) Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve 26:644–653 doi:10.1002/mus.10258 CrossRefPubMed

24.

Haenggi T, Fritschy JM (2006) Role of dystrophin and utrophin for assembly and function of the dystrophin glycoprotein complex in non-muscle tissue. Cell Mol Life Sci 63:1614–1631 doi:10.1007/s00018-005-5461-0 CrossRefPubMed

25.

Inoue M, Wakayama Y, Kojima H, Shibuya S, Jimi T, Oniki H, Nishino I, Nonaka I (2006) Expression of myoferlin in skeletal muscles of patients with dysferlinopathy. Tohoku J Exp Med 209:109–116 doi:10.1620/tjem.209.109 CrossRefPubMed

26.

Guzzo RM, Salih M, Moore ED, Tuana BS (2005) Molecular properties of cardiac tail-anchored membrane protein SLMAP are consistent with structural role in arrangement of excitation-contraction coupling apparatus. Am J Physiol Heart Circ Physiol 288:H1810–H1819 doi:10.1152/ajpheart.01015.2004 CrossRefPubMed

27.

Fu W, Wei J, Gu J (2006) MEF2C mediates the activation induced cell death (AICD) of macrophages. Cell Res 16:559–565 doi:10.1038/sj.cr.7310073 CrossRefPubMed

28.

Robinson FL, Dixon JE (2006) Myotubularin phosphatases: policing 3-phosphoinositides. Trends Cell Biol 16:403–412 doi:10.1016/j.tcb.2006.06.001 CrossRefPubMed

29.

Verde I, Pahlke G, Salanova M, Zhang G, Wang S, Coletti D, Onuffer J, Jin SL, Conti M (2001) Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem 276:11189–11198 doi:10.1074/jbc.M006546200 CrossRefPubMed

Title: Gene expression in blood of subjects with Duchenne muscular dystrophy
Authors: Brenda Wong
Donald L. Gilbert
Wynn L. Walker
Isaac H. Liao
Lisa Lit
Boryana Stamova
Glen Jickling
Michelle Apperson
Frank R. Sharp
Publication date: 01-04-2009
Publisher: Springer-Verlag
Published in: Neurogenetics / Issue 2/2009
Print ISSN: 1364-6745
Electronic ISSN: 1364-6753
DOI: https://doi.org/10.1007/s10048-008-0167-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Gene expression in blood of subjects with Duchenne muscular dystrophy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

An inherited large-scale rearrangement in SACS associated with spastic ataxia and hearing loss

Familial risks for amyotrophic lateral sclerosis and autoimmune diseases

LRRK2 G2019S and R1441G mutations associated with Parkinson’s disease are common in the Basque Country, but relative prevalence is determined by ethnicity

Robust quantification of the SMN gene copy number by real-time TaqMan PCR

Chromosomal microarray mapping suggests a role for BSX and Neurogranin in neurocognitive and behavioral defects in the 11q terminal deletion disorder (Jacobsen syndrome)

Humoral immunodeficiency in congenital insensitivity to pain with anhidrosis